Galcanezumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), G-BA (Germany) and HIRA (South Korea), among others, recommended or restricted galcanezumab, while AOTMIT (Poland) and HAS (France) did not recommend it.
Assessment has run over 6 years, from 2019 at PBAC (Australia) to 2025 at PBAC (Australia).
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The file is active: 4 of 21 records date from 2023 or later.
7 distinct indication wordings are recorded for galcanezumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
6 of these 21 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess galcanezumab, in 2019; PHARMAC (New Zealand) did not open a file until 22 Dec 2023 — a wide spread of 4.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 10 of 21 dated records fall in 2020 alone.
4 of the 13 agencies here assessed galcanezumab more than once, PBAC (Australia) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
galcanezumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for galcanezumab reads 7 recommended, 4 not recommended, 3 other and 3 restricted, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Treatment-resistant high frequency episodic migraine | The PBAC extended the March 2022 recommendation for this drug for a further 12 months. | source |
| PHARMAC (New Zealand) | 22 Dec 2023 | Chronic migraine prevention | PTAC advice: High | source |
| HIRA (South Korea) | 12 May 2022 | 성인에서의 편두통의 예방 | reimbursement appropriate | source |
| AOTMIT (Poland) | 28 Jan 2022 | Emgality reimbursement recommendation | not recommended | source |
| CHUIKYO (Japan) | 14 Apr 2021 | エムガルティ: cost-effectiveness evaluation (new product, high price or high sales) | evaluation completed, price adjustment decided | source |
16 further decisions for galcanezumab, across 11 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- erenumab — same ATC class N02C — Analgesics
- fremanezumab — same ATC class N02C — Analgesics
- atogepant — same ATC class N02C — Analgesics
- rimegepant — same ATC class N02C — Analgesics
- eptinezumab — same ATC class N02C — Analgesics
- sumatriptan — same ATC class N02C — Analgesics
Coverage: 21 decisions for galcanezumab from 13 agencies, 2019 to 2025. Data to 7 Sep 2026. ATC class N02C — Analgesics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.